Wu Lu, Zhang Xianghua, Xia Yong, et al. Application value of prediction of microvascular invasion in the treatment decision‑making of liver and biliary tumors[J]. Chinese Journal of Digestive Surgery, 2024, 23(7): 912-918. DOI: 10.3760/cma.j.cn115610-20240709-00325
Citation: Wu Lu, Zhang Xianghua, Xia Yong, et al. Application value of prediction of microvascular invasion in the treatment decision‑making of liver and biliary tumors[J]. Chinese Journal of Digestive Surgery, 2024, 23(7): 912-918. DOI: 10.3760/cma.j.cn115610-20240709-00325
shu

Application value of prediction of microvascular invasion in the treatment decision‑making of liver and biliary tumors

  • The Fourth Department of Hepatic Surgery, The Third Hospital Affiliated to Naval Medical University, Shanghai200438, China

Funds: 

Clinical Research Project For Health Care of Shanghai Health Commission 202240272

Shanghai Pujiang Talent Project 21PJD015

More Information
  • Corresponding author:

    Shen Feng, Email: shenfengehbh@sina.com

  • Received Date: July 08, 2024
  • Available Online: August 14, 2024
    Graphical Abstract
    • Abstract

  • Microvascular invasion (MVI), which is defined as micro‑metastatic tumor emboli within hepatic micro‑vessels, is deemed as an indicator of biologic traits and one of the determinants of early recurrence and survival of liver and biliary tract tumors after resection. The potential role of prediction of MVI in choosing treatment strategies for patients with liver and biliary tumors has become hotspot in recent years and partly contributed to the improve the discrimination capability of clinical staging by incorporating biologic traits. The diagnosis of MVI still relies on pathological analysis of specimen obtained by resection. Recently, progress of radiological and serological tech-niques has facilitated the preoperative prediction of MVI among patients with liver and biliary tract tumors. The authors attempt to summarize the clinical management of liver and biliary tract tumors based on the decision strategies oriented by prediction of MVI in this article.

    • FullText(HTML)
    • References (60)
  • [1]
    中国医师协会肝癌专业委员会.肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J].中华消化外科杂志,2024,23(2):153‑164. DOI:10.3760/cma.j.cn115610-2024 0125-24041.
    [2]
    JunL, ZhenlinY, RenyanG, et al. Independent factors and predictive score for extrahepatic metastasis of hepatocellu⁃lar carcinoma following curative hepatectomy[J]. Oncologist,2012,17(7):963‑969. DOI: 10.1634/theoncologist.2011-0447.
    [3]
    DhanasekaranR, HemmingAW, ZendejasI, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma[J]. Oncol Rep,2013,29(4):1259‑1267. DOI: 10.3892/or.2013.2290.
    [4]
    ChuKJ, LuCD, DongH, et al. Hepatitis B virus‑related combined hepatocellular‑cholangiocarcinoma: clinicopa-thological and prognostic analysis of 390 cases[J]. Eur J Gastroenterol Hepatol,2014,26(2):192‑199. DOI: 10.1097/MEG.0b013e3283625df9.
    [5]
    ZhangXF, BealEW, ChakedisJ, et al. Defining early recurrence of hilar cholangiocarcinoma after curative‑intent sur-gery: a multi‑institutional study from the us extrahepatic biliary malignancy consortium[J]. World J Surg,2018,42(9):2919‑2929. DOI: 10.1007/s00268-018-4530-0.
    [6]
    HuangX, ShuJ, YanY, et al. Feasibility of magnetic reson-ance imaging‑based radiomics features for preoperative prediction of extrahepatic cholangiocarcinoma stage[J]. Eur J Cancer,2021,155:227‑235. DOI: 10.1016/j.ejca.2021.06.053.
    [7]
    ErstadDJ, TanabeKK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma[J]. Ann Surg Oncol,2019,26(5):1474‑1493. DOI: 10.1245/s10434-019-07227-9.
    [8]
    ShengX, JiY, RenGP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC[J]. Hepatol Int,2020,14(6):1034‑1047. DOI: 10.1007/s12072-020-10111-4.
    [9]
    国家卫生健康委办公厅.原发性肝癌诊疗指南(2022年版)[J].临床肝胆病杂志,2022,38(2):288‑303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [10]
    CongWM, BuH, ChenJ, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update[J]. World J Gastroenterol,2016,22(42):9279‑9287. DOI: 10.3748/wjg.v22.i42.9279.
    [11]
    WangW, GuoY, ZhongJ, et al. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma[J]. Sci Rep,2021,11(1):2415. DOI: 10.1038/s41598-021-82058-x.
    [12]
    HouY, ZouQ, GeR, et al. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers[J]. Cell Res,2012,22(1):259‑272. DOI: 10.1038/cr.2011.139.
    [13]
    MaS. Biology and clinical implications of CD133(+) liver cancer stem cells[J]. Exp Cell Res,2013,319(2):126‑132. DOI: 10.1016/j.yexcr.2012.09.007.
    [14]
    XiaH, KongSN, ChenJ, et al. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence[J]. Cancer Lett,2016,383(1):85‑93. DOI:10.1016/j.canlet.2016. 09.017.
    [15]
    WangK, LiuJ, YanZL, et al. Overexpression of aspartyl-(asparaginyl)‑beta‑hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome[J]. Hepatology,2010,52(1):164‑173. DOI: 10.1002/hep.23650.
    [16]
    ZouQ, HouY, WangH, et al. Hydroxylase activity of ASPH promotes hepatocellular carcinoma metastasis through epithe⁃lial‑to‑mesenchymal transition pathway[J]. EBioMedicine,2018,31:287‑298. DOI: 10.1016/j.ebiom.2018.05.004.
    [17]
    YangT, SongB, ZhangJ, et al. STK33 promotes hepatocellular carcinoma through binding to c‑Myc[J]. Gut,2016,65(1):124‑133. DOI: 10.1136/gutjnl-2014-307545.
    [18]
    LiJ, LiuY, YanZ, et al. A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy[J]. Br J Cancer,2014,110(5):1110‑1117. DOI: 10.1038/bjc.2014.19.
    [19]
    VitaleA, CucchettiA, QiaoGL, et al. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of pati-ents needed to transplant" as measure of transplant benefit[J]. J Hepatol,2014,60(6):1165‑1171. DOI: 10.1016/j.jhep.2014.01.022.
    [20]
    ChoiWJ, WilliamsPJ, ClaasenM, et al. Systematic review and meta‑analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative‑intent resection[J]. Ann Surg Oncol,2022[2024-03-31]. https://pubmed.ncbi.nlm.nih.gov/35181812/. DOI:10.1245/s10 434-022-11463-x. [Online ahead of print].
    [21]
    WuY, LiuH, ZengJ, et al. Development and validation of nomogram to predict very early recurrence of combined hepatocellular‑cholangiocarcinoma after hepatic resection: a multi‑institutional study[J]. World J Surg Oncol,2022,20(1):60. DOI: 10.1186/s12957-022-02536-y.
    [22]
    HuLS, WeissM, PopescuI, et al. Impact of microvascular invasion on clinical outcomes after curative‑intent resection for intrahepatic cholangiocarcinoma[J]. J Surg Oncol,2019, 119(1):21‑29. DOI: 10.1002/jso.25305.
    [23]
    XiaY, QiuY, LiJ, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial[J]. Ann Surg Oncol,2010,17(12):3137‑3144. DOI:10.1245/s104 34-010-1148-3.
    [24]
    HuangLF, XingX, WuD, et al. A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy[J]. Oncotarget,2016,7(18):25493‑25506. DOI: 10.18632/oncotarget.8333.
    [25]
    ChengZ, LeiZ, JinX, et al. Postoperative adjuvant transarterial chemoembolization for intrahepatic cholangiocarcinoma patients with microvascular invasion: a propensity score analysis[J]. J Gastrointest Oncol,2021,12(2):819-830. DOI: 10.21037/jgo-20-443.
    [26]
    LiSH, MeiJ, ChengY, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase Ⅲ, randomized study[J]. J Clin Oncol,2023,41(10):1898‑1908.DOI: 10.1200/JCO.22.01142.
    [27]
    ChenK, XiaY, WangH, et al. Adjuvant iodine‑125 brachytherapy for hepatocellular carcinoma after complete hepa-tectomy: a randomized controlled trial[J]. PLoS One,2013,8(2):e57397. DOI: 10.1371/journal.pone.0057397.
    [28]
    YangP, SiA, YangJ, et al. A wide‑margin liver resection improves long‑term outcomes for patients with HBV-rela-ted hepatocellular carcinoma with microvascular invasion[J]. Surgery,2019,165(4):721‑730. DOI:10.1016/j.surg.2018. 09.016.
    [29]
    HanJ, LiZL, XingH, et al. The impact of resection margin and microvascular invasion on long‑term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study[J]. HPB (Oxford),2019,21(8):962‑971. DOI: 10.1016/j.hpb.2018.11.005.
    [30]
    CucchettiA, QiaoGL, CesconM, et al. Anatomic versus non-anatomic resection in cirrhotic patients with early hepatocellular carcinoma[J]. Surgery,2014,155(3):512‑521. DOI: 10.1016/j.surg.2013.10.009.
    [31]
    ZhangX, LiJ, ShenF, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2018,33(2):347‑354. DOI: 10.1111/jgh.13843.
    [32]
    ZhangZH, JiangC, QiangZY, et al. Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: a literature review[J]. Asian J Surg,2024,47(5):2138‑2143. DOI: 10.1016/j.asjsur.2024.02.115.
    [33]
    WangWT, YangL, YangZX, et al. Assessment of microvascular invasion of hepatocellular carcinoma with diffusion kurtosis imaging[J]. Radiology,2018,286(2):571‑580. DOI: 10.1148/radiol.2017170515.
    [34]
    ChenS, WanL, ZhaoR, et al. Predictive factors of microvascular invasion in patients with intrahepatic mass-for-ming cholangiocarcinoma based on magnetic resonance images[J]. Abdom Radiol (NY),2023,48(4):1306‑1319. DOI: 10.1007/s00261-023-03847-8.
    [35]
    MaX, LiuL, FangJ, et al. MRI features predict microvascular invasion in intrahepatic cholangiocarcinoma[J]. Cancer Imaging,2020,20(1):40. DOI: 10.1186/s40644-020-00318-x.
    [36]
    ZhouY, WangX, XuC, et al. Mass‑forming intrahepatic cholangiocarcinoma: can diffusion‑weighted imaging predict microvascular invasion?[J]. J Magn Reson Imaging,2019,50(1):315‑324. DOI: 10.1002/jmri.26566.
    [37]
    LiaoZJ, LuL, LiuYP, et al. Clinical and DCE‑CT signs in predicting microvascular invasion in cHCC‑ICC[J]. Cancer Imaging,2023,23(1):112. DOI: 10.1186/s40644-023-00621-3.
    [38]
    ZhangJ, DongW, LiuW, et al. Preoperative evaluation of MRI features and inflammatory biomarkers in predicting microvascular invasion of combined hepatocellular cholangiocarcinoma[J]. Abdom Radiol (NY),2024,49(3):710-721. DOI: 10.1007/s00261-023-04130-6.
    [39]
    GuD, XieY, WeiJ, et al. MRI‑based radiomics signature: a potential biomarker for identifying glypican 3‑positive hepa-tocellular carcinoma[J]. J Magn Reson Imaging,2020,52(6):1679‑1687. DOI: 10.1002/jmri.27199.
    [40]
    LeiZ, LiJ, WuD, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria[J]. JAMA Surg,2016,151(4):356‑363. DOI:10.1001/jama surg.2015.4257.
    [41]
    BaiS, YangP, XieZ, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis B virus‑related hepatocellular carcinoma[J]. Ann Surg Oncol,2021,28(13):8174‑8185. DOI: 10.1245/s10434-021-09901-3.
    [42]
    YangP, TengF, BaiS, et al. Liver resection versus liver transplantation for hepatocellular carcinoma within the Milan criteria based on estimated microvascular invasion risks[J]. Gastroenterol Rep (Oxf),2023,11:goad035. DOI: 10.1093/gastro/goad035.
    [43]
    LiZ, LeiZ, XiaY, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus‑related hepatocellular carcinoma[J]. JAMA Surg,2018,153(10):e182721. DOI: 10.1001/jamasurg.2018.2721.
    [44]
    PengZ, WuX, LiJ, et al. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion[J]. Int J Hyperthermia,2022,39(1):688‑696. DOI:10. 1080/02656736.2022.2051613.
    [45]
    WeiX, JiangY, FengS, et al. Neoadjuvant intensity modula-ted radiotherapy for a single and small (≤5 cm) hepatitis B virus‑related hepatocellular carcinoma predicted to have high risks of microvascular invasion: a randomized clinical trial[J]. Int J Surg,2023,109(10):3052‑3060. DOI:10.10 97/JS9.0000000000000574.
    [46]
    YuL, DaiMG, LuWF, et al. Preoperative prediction model for microvascular invasion in HBV‑related intrahepatic cholangiocarcinoma[J]. BMC Surg,2023,23(1):239. DOI: 10.1186/s12893-023-02139-8.
    [47]
    ChenS, ZhuY, WanL, et al. Predicting the microvascular invasion and tumor grading of intrahepatic mass‑forming cholangiocarcinoma based on magnetic resonance imaging radiomics and morphological features[J]. Quant Imaging Med Surg,2023,13(12):8079‑8093. DOI: 10.21037/qims-23-11.
    [48]
    ChenS, WanL, ZhaoR, et al. Nomogram based on preoperative clinical and MRI features to estimate the microvascular invasion status and the prognosis of solitary intrahepatic mass‑forming cholangiocarcinoma[J]. Abdom Radiol (NY),2024,49(2):425‑436. DOI:10.1007/s00261-023-040 79-6.
    [49]
    LiQ, ZhangJ, CaiZ, et al. A bayesian network prediction model for microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multi‑institutional study[J]. World J Surg,2023,47(3):773‑784. DOI: 10.1007/s00268-022-06867-5.
    [50]
    JiangC, ZhaoL, XinB, et al. (18)F‑FDG PET/CT radiomic analysis for classifying and predicting microvascular invasion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Quant Imaging Med Surg,2022,12(8):4135‑4150. DOI: 10.21037/qims-21-1167.
    [51]
    QianX, LuX, MaX, et al. A multi‑parametric radiomics nomogram for preoperative prediction of microvascular invasion status in intrahepatic cholangiocarcinoma[J]. Front Oncol,2022,12:838701. DOI: 10.3389/fonc.2022.838701.
    [52]
    GaoW, WangW, SongD, et al. A multiparametric fusion deep learning model based on DCE‑MRI for preoperative prediction of microvascular invasion in intrahepatic cholangiocarcinoma[J]. J Magn Reson Imaging,2022,56(4):1029-1039. DOI: 10.1002/jmri.28126.
    [53]
    XiangF, WeiS, LiuX, et al. Radiomics analysis of contrast-enhanced ct for the preoperative prediction of microvascular invasion in mass‑forming intrahepatic cholangiocarcinoma[J]. Front Oncol,2021,11:774117. DOI: 10.3389/fonc.2021.774117.
    [54]
    ZhangJ, DongW, LiY, et al. Prediction of microvascular invasion in combined hepatocellular‑cholangiocarcinoma based on preoperative contrast‑enhanced CT and clinical data[J]. Eur J Radiol,2023,163:110839. DOI: 10.1016/j.ejrad.2023.110839.
    [55]
    ZhouG, ZhouY, XuX, et al. MRI‑based radiomics signature: a potential imaging biomarker for prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma[J]. Abdom Radiol (NY),2024,49(1):49‑59. DOI:10. 1007/s00261-023-04049-y.
    [56]
    HuangSS, ZuoMX, XieCM. Combining preoperative clinical and imaging characteristics to predict MVI in hepatitis B virus‑related combined hepatocellular carcinoma and cholangiocarcinoma[J]. J Pers Med,2023,13(2):246. DOI:10. 3390/jpm13020246.
    [57]
    ChenY, LuQ, ZhuY, et al. Prediction of microvascular invasion in combined hepatocellular‑cholangiocarcinoma based on pre‑operative clinical data and contrast-enhanced ultra-sound characteristics[J]. Ultrasound Med Biol,2022,48(7):1190‑1201. DOI: 10.1016/j.ultrasmedbio.2022.02.014.
    [58]
    WangY, ZhouCW, ZhuGQ, et al. A multidimensional nomo-gram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepa-tocellular cholangiocarcinoma[J]. Ann Transl Med,2021,9(20):1518. DOI: 10.21037/atm-21-2500.
    [59]
    WangX, WangW, MaX, et al. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?[J]. Eur Radiol,2020,30(10):5337‑5347. DOI:10.1007/s00 330-020-06861-2.
    [60]
    赵建新,潘妮妮,何迪梁,等.增强CT检查预测肝细胞癌微血管侵犯的影像基因组学研究[J].中华消化外科杂志,2023,22(11):1367-1377. DOI:10.3760/cma.j.cn115610-202310 13-00148.
    • Related Articles

  • Related Articles

    [1]Cao Guoliang, Cai Qing, Li You′an, Zhang Qifan, Zhou Jie.. Risk factors analysis and prognosis of the microvascular invasion of hepatocellular carcinoma[J]. Chinese Journal of Digestive Surgery, 2017, 16(10): 1048-1052. DOI: 10.3760/cma.j.issn.1673-9752.2017.10.013
    [2]Chen Luchuan, Wei Shenghong, Ye Zaisheng, Lin Zhenmeng, Chen Xiaoling, Zeng Yi, Wang Yi, Li Yangming, Xiao Jun.. Effect of perineural invasion in prognosis of 1801 patients undergoing radical resection of gastric cancer[J]. Chinese Journal of Digestive Surgery, 2017, 16(3): 262-268. DOI: 10.3760/cma.j.issn.1673-9752.2017.03.009
    [3]Cheng Ya, Jia Weidong, Xing Songge, Xu Geliang.. Clinical efficacy of anatomic liver resection in the treatment of hepatocellular carcinoma with microvascular invasion[J]. Chinese Journal of Digestive Surgery, 2017, 16(2): 144-150. DOI: 10.3760/cma.j.issn.1673-9752.2017.02.008
    [4]Tong Li, Geng Xiaoping, Xie Kun, Zhao Hongchuan, Liu Fubao.. Reasons and prognosis of multiple-operations for intra-and extrahepatic cholangiolithiasis[J]. Chinese Journal of Digestive Surgery, 2016, 15(4): 368-373. DOI: 10.3760/cma.j.issn.1673-9752.2016.04.012
    [5]Zhang Hongdian, Tang Peng, Yue Jie, Yu Zhentao. Effects of tumor diameter on the prognosis of patients with advanced esophageal squamous cell carcinoma after IvorLewis surgical resection[J]. Chinese Journal of Digestive Surgery, 2015, 14(7): 569-573. DOI: 10.3760/cma.j.issn.1673-9752.2015.07.012
    [6]Li Jian′ang, Han Xu, Fang Yuan, Zhao Jing, Ji Yuan, Lou Wenhui, Xu Xuefeng. Clinical features and prognosis of gastric neuroendocrine neoplasms[J]. Chinese Journal of Digestive Surgery, 2014, 13(10): 784-788. DOI: 10.3760/cma.j.issn.1673-9752.2014.10.009
    [7]Li Junqiang, Liu Zhong, Hu Xiang. Treatment and prognosis of primary gastric lymphoma[J]. Chinese Journal of Digestive Surgery, 2014, 13(8): 625-628. DOI: 10.3760/cma.j.issn.1673-9752.2014.08.009
    [8]JIANG Yong, WU Tao, WAN Yuan lian, WANG Xin, YIN Hong fang, LIU Yu cun. Surgical treatment and prognosis analysis of cT4bM0 primary rectal cancer[J]. Chinese Journal of Digestive Surgery, 2013, 12(6): 417-421. DOI: 10.3760/cma.j.issn.1673-9752.2013.06.005
    [9]WANG Fei, YANG Ning, ZHANG Hai bin, ZHAO Jun, YANG Guang shun. Expression of MTSS1 in cholangiocarcinoma tissue and its relationship with the prognosis of patients[J]. Chinese Journal of Digestive Surgery, 2013, 12(5): 383-387. DOI: 10.3760/cma.j.issn.1673-9752.2013.05.014
    [10]DONG Na na, DUAN Xiao feng, ZHANG Ti, LI Hui kai, ZHOU Hong yuan, NIU Guangcai, SHEN Changming, LI Qiang. Analysis of treatment and prognosis of primary gallbladder cancer[J]. Chinese Journal of Digestive Surgery, 2012, 11(3): 267-270. DOI: 10.3760/cma.j.issn.1673-9752.2012.03.020

Catalog

    Get Citation
    PDF
    XML
    Article views (6) PDF downloads (5) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return